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1 Drug description 
Generic/Brand name/ATC code:  
Afatinib/Giotrif
®
 (Europe), Gilotrif
®
 (US)/L01XE13 
Developer/Company:  
Boehringer Ingelheim International GmbH 
Description:  
Afatinib is an orally bioavailable receptor tyrosine kinase inhibitor (TKI) 
with antineoplastic activity. Human epidermal growth factor receptors 1 
(ErbB1; EGFR), 2 (ErbB2; HER2) and 4 (ErbB4; HER4) and certain EGFR 
mutants (including those caused by EGFR exon 19 deletion mutations or 
exon 21 (L858R) mutations) play a major role in tumour cell proliferation 
and tumour vascularisation and are overexpressed in many cancer cell types. 
Afatinib inhibits these receptors and therefore tumour growth by 
irreversible binding [1-4]. 
The recommended dose of Giotrif
®
 is 40 mg orally once daily until disease 
progression or unacceptable toxicity [5]. 
 
 
2 Indication 
Afatinib (Giotrif
®
) as monotherapy is indicated for the treatment of EGFR 
TKI-naïve adult patients with locally advanced or metastatic non-small cell 
lung cancer (NSCLC) with activating EGFR mutations. 
 
 
3 Current regulatory status 
In September 2013, the EMA granted marketing authorisation for Giotrif
®
 
20 mg, 30 mg, 40 mg and 50 mg film-coated tablets 
 intended for the treatment of EGFR TKI-naïve adult patients with 
locally advanced or metastatic NSCLC with activating EGFR 
mutations [2]. 
The US Food and Drug Administration (FDA) approved afatinib (Gilotrif
®
) 
on 12 July 2013 for  
 the first-line treatment of patients with metastatic NSCLC whose 
tumours have EGFR mutations [6]. 
afatinib is a tyrosine 
kinase inhibitor of EGFR 
40 mg orally daily 
administered 
for EGFR TKI-naïve 
patients  with advanced 
or metastatic NSCLC 
EMA licensed afatinib in 
September 2013 
 
 
 
 
FDA licensed afatinib in 
July 2013 
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4 Burden of disease 
Lung cancer accounts for more than 11% of all malignant neoplasms in 
Austria and is the leading cause of death due to cancer in males. In 2010, 
about 2,700 men and 1,200 women were newly diagnosed with lung cancer in 
Austria and 3,650 people died [7]. The majority of lung cancer patients are 
diagnosed at an age ≥ 65 years and the median age at diagnosis for lung 
cancer is 70 years [8]. 
 
The most important risk factor associated with lung cancer is tobacco 
smoking, accounting for about 90% of all lung cancers. Besides exposure to 
tobacco smoke, additional environmental factors and genetic predisposition 
affect the risk for lung cancer [9]. 
 
Lung cancer can be differentiated into two major classes, i.e. NSCLC and 
small cell lung cancer (SCLC). NSCLC accounts for more than 85% of all 
lung cancer cases and includes two major types:  
 non-squamous carcinoma (including adenocarcinoma, large-cell 
carcinoma, and other cell types) 
 squamous cell (epidermoid) carcinoma [10]. 
Based on the tumour node metastasis (TNM) staging system which 
considers tumour size, location and invasion of the surrounding tissue, 
presence of metastasis in the lymph nodes or distant metastasis, four stages 
are distinguished. Locally advanced and metastasised NSCLC corresponds 
to TNM stage IIIB and IV [11]. 
NSCLC can further be differentiated into EGFR mutational status positive 
or negative. Due to the development of targeted therapies, EGFR mutational 
status should also be assessed prior to therapy [10]. Some guidelines 
recommend routine testing for EGFR mutations only for non-squamous 
NSCLC (which comprises adenocarcinomas, the most frequent histo-
pathological subtype) because EGFR mutations in squamous cell 
carcinomas are rather rare [10, 12, 13]. The two most common mutations are 
exon 19 deletions (50%) and L858R point mutations (40%) [14]. In addition 
to EGFR, other onco-genetic mutations have been identified, e.g. anaplastic 
lymphoma kinase (ALK) or rat sarcoma (RAS) mutations [15, 16]. 
 
 
 
5 Current treatment 
Modalities for the treatment of NSCLC which are generally used are 
surgery, radiation therapy, chemotherapy and targeted therapy. Depending 
on disease status, Eastern Cooperative Oncology Group (ECOG) 
performance status and prognostic factors, these treatments can be used 
either alone or in combination [12]. 
First-line therapy of advanced NSCLC depends on a number of factors, such 
as tumour stage, histo-pathological subtype and performance status. Current 
treatment options for the first-line therapy of patients with advanced or 
metastatic lung cancer are: 
leading cause of death 
due to cancer in 
Austrian males 
tobacco smoking as 
most important risk 
factor 
two types: SCLC and 
NSCLC 
advanced or metastatic 
NSCLC complies with 
TNM stage IIIB and IV 
assessment of 
mutational status  
surgery, radiation 
therapy, chemotherapy 
and targeted therapy  
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 double-agent chemotherapy regimen based on a platinum 
compound (cisplatin, carboplatin) in addition to one out of 
numerous other substances (paclitaxel, gemcitabine, vinorelbine or 
docetaxel and pemetrexed) 
 other chemotherapy regimens: due to the toxicity of platinum-
based regimens, other drug combinations can be used (gemcitabine 
+ docetaxel/paclitaxel/vinorelbine/pemtrexed, paclitaxel + 
vinorelbine) 
 single-agent chemotherapy as first-line treatment may be used for 
elderly patients 
 targeted therapies: EGFR inhibitors (erlotinib, gefitinib), 
monoclonal antibodies (bevacizumab) 
 a combined modality approach [10, 12, 15]. 
If patients are EGFR mutational status positive, EGFR-TK inhibitors 
(e.g. erlotinib, gefitinib) are increasingly used as standard first-line 
therapy, whereas patients with either unknown EGFR status or without 
EGFR mutation receive chemotherapy doublets, either alone or in 
combination with a monoclonal antibody (bevacizumab). If patients 
with driver mutations have initially been treated with chemotherapy, 
targeted therapy with a specific inhibitor is indicated after progression 
on the initial chemotherapy regimen either alone or in combination 
with chemotherapy [15, 16]. 
 
 
6 Evidence 
A literature search was conducted on the 23
rd
 of September 2013 in 4 databases 
(Medline, Embase, CRD, Cochrane Central), resulting in 83 references. 
Search terms were “non-small cell lung cancer”, “afatinib” or “Giotrif”. 
Eligible for inclusion were phase III trials (full text, abstracts) and phase 
II studies published as full text but also other study designs such as results 
from compassionate-use programmes or meta-analyses. Also, the 
manufacturer was contacted for any further evidence and 9 studies were 
submitted. Of these, 7 had already been identified by the systematic 
literature search, resulting in 2 additional references. Overall, 85 references 
were identified. 
After applying the inclusion criteria, two phase III trials [3, 17] and one phase 
II trial [18] were included in this report. 
 
 
 
 
double-agent platinum-
based chemotherapy 
other combinations due 
to platinum toxicity 
single-agent 
chemotherapy  
targeted therapies 
combined approach 
first and second-line 
treatment depending on 
mutations 
literature search in 4 
databases: 83 hits 
 
 
 
manufacturer 
information 
 
 
 
 
included: 2 phase III, 1 
phase II 
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6.1 Efficacy and safety – phase III studies 
Table 1: Summary of efficacy of the LUX-Lung 3 trial 
Study title  
LUX-Lung 3 trial: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung 
adenocarcinoma with EGFR mutations [3] 
Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin plus 
pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations [19] 
Source of 
information 
Full texts [3, 19], FDA Document [20] 
Study  
identifier 
ClinicalTrials.gov Identifier: NCT00949650, EudraCT Number: 2008-005615-18 
Design Randomised, open-label, multicentre (133 centers in 25 countries) phase III study, 2:1 
ratio  
Duration  Enrolment: August 2009 – February 2011 
Median follow-up: 16.4 months 
Cut-off dates for primary analysis: February 2012 (PFS), January 
2013 (OS) [20] 
Cut-off date for final analyses: December 2013 
Hypothesis Superiority 
Funding Boehringer Ingelheim International GmbH 
Treatment 
groups 
Intervention 
(n=230) 
Afatinib 40 mg orally (once per day), until investigator-assessed 
progression 
Control 
(n=115) 
Cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 intravenously 
(once every 21 days up to a maximum of six cycles) until 
investigator-assessed progression 
Endpoints 
and 
definitions 
Progression-free 
survival 
(primary 
outcome) 
PFS Time from random assignment to progression or death 
as assessed by an independent review committee 
Objective 
response rate 
ORR The proportion of patients with best overall RECIST 
response of CR or PR, divided by the total number of 
patients randomly assigned to that arm 
Disease control 
rate 
DCR Proportion of patients with CR/PR+SD 
Duration of 
response 
DOR Time from the first documented response until disease 
progression or death from any cause 
Overall survival OS Time interval from date of randomisation to death from 
any cause 
Patient-reported 
outcomes 
PROs Measured with: 
 EORTC QLQ-C30 
 EORTC QLQ-LC13 (lung cancer-specific module) 
PROs were assessed per standard published EORTC 
algorithms, including time to deterioration of symptoms 
calculated as the time from random assignment to the 
first 10-point worsening from the baseline score 
(considered clinically meaningful) 
Adverse events AEs Categorised and graded using NCI-CTCAE version 3.0 
Pharmacokinetics – Plasma concentrations analysed by validated high-
performance liquid chromatography tandem mass 
spectrometry 
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Results and analysis 
Analysis  
description 
ITT 
PFS was compared by a stratified log-rank test, Cox proportional hazard models and 
Kaplan-Meier estimates. Median follow-up time was calculated with the reverse Kaplan-
Meier method. Descriptive statistics were used for all other secondary and exploratory 
analyses. 
Analysis  
population 
Inclusion  Treatment-naïve advanced lung adenocarcinoma 
 Pathologically confirmed diagnosis of stage IIIB or stage IV 
adenocarcinoma of the lung 
 Tumours harbour an activating mutation in EGFR  
 Good performance status, defined as 0 or 1 on the ECOG scale 
 Adequate end-organ function 
 Measurable disease according to RECIST 1.1 
Exclusion  Prior chemotherapy for relapsed and/or metastatic NSCLC 
 Neoadjuvant/adjuvant chemotherapy if at least 12 months has 
elapsed between the end of chemotherapy and randomisation 
 Prior treatment with EGFR targeting small molecules or 
antibodies 
 Radiotherapy or surgery (other than biopsy) within 4 weeks 
prior to randomisation 
 Active brain metastases 
 Any other current malignancy or malignancy diagnosed within 
the past five years 
 Known pre-existing interstitial lung disease 
 Significant or recent acute gastrointestinal disorders with 
diarrhoea as a major symptom  
 History or presence of clinically relevant cardiovascular 
abnormalities 
Characteristics Age – median (range) (years): I 61.5 (28–86) vs C 61.0 (31–83) 
Male/female, n (%): I 83 (36.1)/147 (63.9) vs C 38 (33.0)/77 (67.0) 
Race, n (%):  
- White: I 61 (26.5) vs C 30 (26.1) 
- East Asian: I 165 (71.7) vs C 83 (72.2) 
- Other: I 4 (1.7) vs C 2 (1.7) 
Smoking status, n (%): 
- Never: I 155 (67.4) vs C 81 (70.4) 
- Former: I 70 (30.4) vs C 32 (27.8) 
- Current: I 5 (2.2) vs C 2 (1.7) 
ECOG – 0/1/2 (%): I 40/60/0 vs C 35.7/63.5/0.9 
Adenocarcinoma stage, n (%): 
- IIIB with pleural effusion: I 20 (8.7) vs C 17 (14.8) 
- IV: I 210 (91.3) vs C 98 (85.2) 
EGFR mutation, n (%): 
- Exon 19 deletion: I 113 (49.1) vs C 57 (49.6) 
- L858R: I 91 (39.6) vs C 47 (40.9) 
- Other: I 26 (11.6) vs C 11 (9.6) 
Descriptive 
statistics 
and 
estimated 
variability 
 Afatinib Cisplatin+pemetrexed 
Overall study population N=230 N=115 
Median PFS – all patients, 
months  
95% CI 
11.1  
 
9.6–13.6 
6.9 
 
5.4–8.2 
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ORR, % 
Complete Response 
Partial Response 
56.1 
0.4 
55.7 
23 
0.0 
22.6 
DCR, % 90 81 
Median DOR, months 11.1 5.5 
Median OS (95% CI), 
months 
Updated analysis [21] 
16.6 (NR) 
 
28.1 (24.6–33.0) 
14.8 (NR) 
 
28.2 (20.7–33.2) 
Median time to 
deterioration for 
cough/dyspnoea/pain, 
months 
NE/10.3/4.2 8.0/2.9/3.1 
Subgroup analyses   
Patients with common 
EGFR mutations  
N=204 
 
N=104 
Median PFS, months 13.6 6.9 
Patients with uncommon 
EGFR mutations  
N=26 N=11 
Median PFS, months 2.8 9.9 
Effect 
estimate per 
comparison 
Overall study population  Intervention vs Control 
PFS – all patients HR 0.58 
95% CI 0.43–0.78 
P value 0.001 
Median OS (updated 
analysis [21]) 
HR 1.12 
95% CI 0.73–1.73 
P value 0.6 
Time to deterioration of 
cough 
HR 0.60 
95% CI 0.41–0.87 
P value 0.007 
Time to deterioration of 
dyspnoea 
HR 0.68 
95% CI 0.50–0.93 
P value 0.015 
Time to deterioration of 
pain 
HR 0.83 
95% CI 0.62–1.10 
P value 0.19 
Subgroup analyses PFS   
PFS, patients with 
common EGFR mutations  
HR 0.47 
95% CI 0.34–0.65 
P value 0.001 
PFS, patients with 
uncommon EGFR 
mutations 
HR 1.89 
95% CI 0.84–4.28 
P value NR 
Sex 
Male/Female 
HR 0.61/0.54 
95% CI 0.37–1.01/0.38–0.78 
P value 0.85 
Age at baseline, years: 
<65/≥65 
HR 0.53/0.64 
95% CI 0.36–0.76/0.39–1.03 
 LBI-HTA | 2013 9 
P value 0.58 
Race: 
Non-Asian/Asian 
HR 0.68/0.54 
95% CI 0.39–1.19/0.38–0.76 
P value 0.65 
Baseline ECOG score: 
0/1 
HR 0.50/0.63 
95% CI 0.31–0.82/0.43–0.91 
P value 0.60 
Smoking history: 
Never smoked/<15 packet 
years+stop > 1 
year/current or ex-smoker 
HR 0.47/0.50/1.04 
95% CI 0.33–0.67/0.19–1.34/0.54–
1.98 
P value 0.09 
Abbreviations: AEs = adverse events, CI = confidence interval, CR = complete response, DCR = disease control rate, DOR = 
duration of response, ECOG = Eastern Cooperative Oncology Group, EGFR = epidermal growth factor receptor, EORTC-
QLQ = European Organisation for Research and Treatment of Cancer – core quality-of-life questionnaire, HR = hazard 
ratio, ITT = intention to treat, N = number, NCI-CTCAE = National Cancer Institute – common terminology criteria for 
adverse events, NE = not evaluable, NR = not reported, NSCLC = non-small cell lung cancer, OS = overall survival, ORR 
= objective response rate, PFS = progression-free survival, PR = partial response, PROs = patient-reported outcomes, 
RECIST = response evaluation criteria in solid tumours, SD = stable disease 
 
Table 2: Most frequent adverse events of the LUX-Lung 3 trial 
NCT00949650 
Adverse event* (according to CTC 
version 3.0) 
Afatinib (n=229) Cisplatin+pemetrexed (n=111) 
All Grades 
n (%) 
Grade≥3 
n (%) 
All Grades 
n (%) 
Grade≥3 
n (%) 
Diarrhoea 218 (95.2) 33 (14.4) 17 (15.3) 0 (0.0) 
Rash/acne 204 (89.1) 37 (16.2) 7 (6.3) 0 (0.0) 
Stomatitis/mucositis 165 (72.1) 20 (8.7) 17 (15.3) 1 (0.9) 
Paronychia 130 (56.8) 26 (11.4) 0 (0.0) 0 (0.0) 
Dry skin 67 (29.3) 1 (0.4) 2 (1.8) 0 (0.0) 
Decreased appetite 47 (20.5) 7 (3.1) 59 (53.2) 3 (2.7) 
Pruritus 43 (18.8) 1 (0.4) 1 (0.9) 0 (0.0) 
Nausea 41 (17.9) 2 (0.9) 73 (65.8) 4 (3.6) 
Fatigue 40 (17.5) 3 (1.3) 52 (46.8) 14 (12.6) 
Vomiting 39 (17.0) 7 (3.1) 47 (42.3) 3 (2.7) 
Epistaxis 30 (13.1) 0 (0.0) 1 (0.9) 1 (0.9) 
Cheilitis 28 (12.2) 0 (0.0) 1 (0.9) 0 (0.0) 
Anaemia 7 (3.1) 1 (0.4) 31 (27.9) 7 (6.3) 
Constipation 6 (2.6) 0 (0.0) 21 (18.9) 0 (0.0) 
Leukopenia 4 (1.7) 1 (0.4) 21 (18.9) 9 (8.1) 
Neutropenia 2 (0.9) 1 (0.4) 35 (31.5) 20 (18.0) 
Abbreviations: CTC = common toxicity criteria, n = number 
* Events were included if reported in > 10% of patients in either treatment group and if there was ≥ 10% 
difference between the groups. Events are listed according to incidence in the afatinib group. 
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The LUX-Lung 3 trial (a randomised, open-label, multicentre phase III 
study) aimed to assess the efficacy and safety of afatinib in patients with 
metastatic NSCLC whose tumours have EGFR mutations [3]. The trial 
compared first-line treatment with afatinib (n=230) to cisplatin plus 
pemetrexed (n=115). Patients in the intervention group received afatinib 40 
mg orally (once per day), while patients in the control group received 
cisplatin 75 mg/m
2
 and pemetrexed 500 mg/m
2
 intravenously (once every 21 
days up to a maximum of six cycles). 
The patients included had a median age of 61 years. The vast majority of the 
study population had never been smokers and had a good ECOG 
performance status (0 or 1). Since EGFR mutations are more common in 
women, never-smokers and Asians, this EGFR-enriched study population 
contained, as expected, mainly individuals with these characteristics. 
For patients treated with afatinib, median PFS – the primary outcome – was 
extended by 4.2 months (11.1 vs. 6.9 months, HR 0.58, p=0.001) as 
determined by independent review. Secondary endpoints including objective 
response rate (56% with afatinib and 23% with cisplatin and pemetrexed) 
and duration of response (median duration of response for afatinib: 11.1 
months compared with 5.5 months in the control group) favoured patients 
treated with afatinib. Subgroup analyses consistently favoured the afatinib 
group with the exception of the rather small (n=37) subgroup of patients 
with uncommon EGFR mutations (HR 1.89, CI 0.84–4.28, p=NR). Only 
preliminary results were reported for median OS in the publication but an 
updated analysis was found in the FDA licensing documents (28.1 vs. 28.2 
months, HR=1.12, p=0.6) [21]. However, due to high post-progression 
crossover (62%–65%), results may be influenced by crossover. 
Health-related quality of life was assessed using the European Organisation 
for Research and Treatment of Cancer’s quality-of-life questionnaire C30 
(EORTC QLQ-C30) and a specific version for lung cancer patients (QLQ-
LC13). Administration of afatinib resulted in a significantly delayed time to 
deterioration for cough and dyspnoea, but not for pain. It is important to 
note that a subgroup analysis in patients with EGFR common mutations 
demonstrated an increase in symptom improvement and control the higher 
the gains in PFS were [19]. 
 
Toxicity profiles rather differed between the two groups. While 
haematological AEs (e.g. anaemia, neutropenia) were more common with 
chemotherapy, skin-related AEs were more common with afatenib. 
Diarrhoea (95%), rash/acne (89%), stomatitis/mucositis (72%) and 
paronychia (57%) were the most frequent AEs with afatinib, whereas 
decreased appetite (53%), fatigue (47%), vomiting (42%) and neutropenia 
(31%) were the most commonly observed AEs in the control group. 
Occurrence of AEs grade ≥ 3 was comparable (afatinib: 49% vs 
chemotherapy: 48%). Therapy was discontinued because of treatment-
related AEs in 8% of the patients receiving afatinib and in 12% of the 
patients receiving cisplatin plus pemetrexed. Dose reduction to less than 40 
mg afatinib per day was required for 120 patients (52%) and 19% required 
more than one dose reduction. 
 
 
LUX-Lung 3 investigated 
efficacy and safety of 
afatinibin in 345 
patients 
median age of 61 years 
and ECOG performance 
status 0 or 1 
median PFS was 
extended by 4.2 months 
in the afatinib group 
 
secondary endpoints 
and subgroup analyses 
favoured patients 
treated with afatinib 
afatinib delayed time to 
deterioration for cough 
and dyspnoea, but not 
for pain 
haematological AEs 
more common with 
chemotherapy, skin-
related AEs more 
common with afatinib 
 
therapy discontinuation 
in 8% of patients with 
afatinib, 12 % with 
chemotherapy 
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Table 3: Summary of efficacy of the LUX-Lung 6 trial 
Study title  
LUX-Lung 6: A randomized, open-label, phase III study of afatinib versus gemcitabine/cisplatin as first-
line treatment for Asian patients with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma 
of the lung [17] 
LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-
line advanced NSCLC patients harboring EGFR mutations [22] 
Source of 
information 
Based on abstracts and posters [17, 22] 
Study  
identifier 
ClinicalTrials.gov Identifier: NCT01121393  
Design randomised, open-label, multicentre (36 sites in 3 Asian countries) phase III study, 2:1 
ratio  
Duration  Enrolment: April 2010-November 2011 
Median follow-up: NR 
Cut-off date for primary analysis: 29 October 2012 
Hypothesis Superiority 
Funding Boehringer Ingelheim International GmbH 
Treatment 
groups 
Intervention 
(n=242) 
Afatinib 40 mg orally (once per day), until progression or 
unacceptable AEs 
Control 
(n=122) 
Gemcitabine 1000 mg/m2 (on day 1 and day 8) plus cisplatin 75 
mg/m2 intravenously (on day 1) of each 21-day cycle up to a 
maximum of six cycles 
Endpoints 
and 
definitions 
Progression-free 
survival 
(primary 
outcome) 
PFS Time from random assignment to progression or death 
based on independent radiology review and determined 
by RECIST 1.1 
Objective 
response rate 
ORR The proportion of patients with best overall RECIST 
response of CR or PR, divided by the total number of 
patients randomly assigned to that arm 
Disease control 
rate 
DCR NR 
Duration of 
response 
DOR Time from the first documented response until disease 
progression or death from any cause 
Tumour shrinkage – NR 
Overall survival OS Time interval from date of randomisation to death from 
any cause 
Patient-reported 
outcomes 
PROs Measured with: 
 EQ-5D 
 EORTC QLQ-C30 
 EORTC QLQ-LC13 (lung cancer-specific module) 
Measured at: randomisation and every 3 weeks until 
progression or new anticancer therapy 
Prespecified symptoms of interest were cough, dyspnoea 
and pain 
Safety and 
pharmacokinetics 
– Intensity and incidence of AEs were described using the 
NCI-CTCAE Version 3.0 
Results and analysis 
Analysis  
description 
ITT 
Stratified log-rank and Cox proportional hazard for PFS comparisons 
Analysis  Inclusion  Pathologically confirmed diagnosis of stage IIIB (wet) or stage IV 
Horizon Scanning in Oncology 
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population adenocarcinoma of the lung 
 EGFR mutation in the tumour sample 
 Measurable disease (RECIST 1.1) 
 No prior chemotherapy or EGFR-targeting drugs for advanced 
non-small cell lung cancer (NSCLC) 
 ECOG performance status 0 or 1 
 Adequate organ function 
Exclusion  Prior chemotherapy or EGFR-targeting drugs for advanced 
NSCLC 
 Asymptomatic brain metastases 
Characteristics Age – median (range) (years): I 58 (29–79) vs C 58 (27–76) 
Male/female, n (%): I 87 (36)/155 (64) vs C 39 (32)/83 (68) 
Smoking status, n (%): 
- Never: I 181 (75) vs C 99 (81) 
- Former: I 44 (18) vs C 13 (11) 
- Current: I 17 (7) vs C 10 (8) 
ECOG – 0/1, n (%): I 48 (20)/194 (80) vs C 41 (34)/81 (66) 
Adenocarcinoma stage, n (%): 
- IIIB (wet): I 16 (7) vs C 6 (5) 
- IV: I 226 (93) vs C 116 (95) 
EGFR mutation, n (%): 
- Exon 19 deletion: I 124 (51) vs C 62 (51) 
- L858R: I 92 (38) vs C 46 (38) 
- Other: I 26 (11) vs C 14 (12) 
Descriptive 
statistics 
and 
estimated 
variability 
Treatment group Afatinib Gemcitabine+cisplatin 
Number of subjects N=242 N=122 
Median PFS, months  11.0 5.6 
12-month PFS rate, % 47.0 2.0 
ORR, % 66.9 23.0 
DCR, % 92.6 76.2 
Median DOR, months, 
(95% CI) 
9.7 
(8.3–12.5) 
4.3 
(2.8–5.8) 
Median duration of disease 
control, months, (95% CI) 
11.1 
(9.7–13.8) 
5.7 
(5.5–6.9) 
Median OS, months 22.1 22.2 
Median time to 
deterioration, 
months/symptom 
improvement (≥10 points), 
% 
cough 
dyspnoea 
pain 
 
 
 
 
 
NR/76 
7.7/71 
6.4/64 
 
 
 
 
10.3/55 
1.7/48 
3.4/47 
Effect 
estimate per 
comparison 
Comparison groups  Intervention vs Control 
PFS HR 0.28 
95% CI 0.20–0.39 
P value p<0.0001 
ORR OR 7.282 
95% CI NR 
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P value p<0.0001 
DCR OR 3.843 
95% CI NR 
P value p<0.0001 
OS OR 0.95 
95% CI NR 
P value 0.7593 
Time to deterioration of 
cough 
HR 0.45 
95% CI 0.30–0.68 
P value p=0.0001 
Time to deterioration of 
dyspnoea 
HR 0.54 
95% CI 0.40–0.73 
P value p<0.0001 
Time to deterioration of 
pain 
HR 0.70 
95% CI 0.51–0.96 
P value p=0.03 
Global health status HR 0.56 
95% CI 0.41–0.77 
P value NR 
Subgroup analyses PFS: 
Sex: 
Male/Female 
HR 0.36/0.24 
95% CI 0.21–0.63/0.16–0.35 
P value NR 
Age at baseline, years: 
<65/≥65 
HR 0.30/0.16 
95% CI 0.21–0.43/0.07–0.40 
P value NR 
EGFR mutation category: 
Exon 19 deletion or L858R 
(common)/exon 19 
deletion/L858R/other 
(uncommon) 
HR 0.25/0.20/0.32/0.55 
95% CI 0.18–0.35/0.13–0.33/0.19–
0.52/0.22–1.43 
P value NR 
Baseline ECOG score: 
0/1 
HR 0.22/0.29 
95% CI 0.12–0.41/0.20–0.43 
P value NR 
Smoking history: 
Never smoked/<15 packet 
years+stop>1 year/current 
or ex-smoker 
HR 0.24/0.39/0.46 
95% CI 0.16–0.34/0.07–2.41/0.22–
1.00 
P value NR 
Abbrevations: AEs = adverse events, CI = confidence interval, DCR = disease control rate, DOR = duration of 
response, ECOG = Eastern Cooperative Oncology Group, EGFR = epidermal growth factor receptor, EORTC-
QLQ = European Organisation for Research and Treatment of  
Cancer – core quality-of-life questionnaire, HR = hazard ratio, ITT = intention to treat, N = number, NCI-
CTCAE = National Cancer Institute – common terminology criteria for adverse events, NR = not reported, 
NSCLC = non-small cell lung cancer, ORR = objective response rate, OS = overall survival, PFS = 
progression-free survival, PROs = patient-reported outcomes, RECIST = response evaluation criteria in solid 
tumours 
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Table 4: Safety summary of the LUX-Lung 6 trial 
AEs, % Afatinib (n=239) Gemcitabine+cisplatin (n=113) 
Drug-related AEs  98.7 99.1 
Drug-related AEs Grade≥3  36.0 60.2 
Drug-related AEs leading to dose reduction 32.2 26.5 
Drug-related AEs leading to 
discontinuation 
5.9 39.8 
Drug-related serious AEs  5.4 7.0 
Related AEs leading to death‡  0.4 0.9 
Abbrevations: AEs = adverse events 
Table 5: Most frequent adverse events of the LUX-Lung 6 trial 
NCT01121393 (abstracts, poster) 
AEs* (according to 
CTC version 3.0) 
Afatinib (n=239) Gemcitabine+cisplatin (n=113) 
All Grades, % Grade  3, % Grade  4, % All Grades, % Grade  3, % Grade  4, % 
Diarrhoea 88.3 5.4 0.0 10.6 0.0 0.0 
Rash/acne 80.8 14.2 0.4 8.8 0.0 0.0 
Stomatitis/mucositis 51.9 5.4 0.0 5.3 0.0 0.0 
Paronychia 32.6 0.0 0.0 0.0 0.0 0.0 
ALT increase 20.1 1.7 0.0 15.9 1.8 0.9 
Vomiting 9.6 0.8 0.0 80.5 15.9 3.5 
Nausea 7.5 0.0 0.0 75.2 7.1 0.9 
Neutropenia 2.1 0.4 0.0 54.0 17.7 8.8 
Leukopenia 3.3 0.4 0.0 51.3 13.3 1.8 
Decreased appetite 10.0 1.3 0.0 40.7 1.8 0.0 
Fatigue 10.0 0.4 0.0 36.3 0.9 0.0 
Anaemia 5.4 0.4 0.0 27.4 7.1 1.8 
Neutrophil count 
decreased 
0.8 0.0 0.0 25.7 7.1 2.7 
WBC decreased 0.8 0.0 0.0 23.9 6.2 0.0 
Abbrevations: AEs = adverse events, ALT = alanine transaminase, CTC = common toxicity criteria, WBC = 
white blood cells 
*most frequently reported drug-related AEs: >20% 
 
 
Results of the LUX-Lung 6 study have not been fully published yet, but 
preliminary results are published as posters and conference abstracts. This 
study (an open-label, randomised, multicentre phase III trial) investigated 
the efficacy and safety of afatinib for Asian patients with EGFR mutation-
positive advanced NSCLC. A total of 364 patients were randomised to 
receive either afatinib (n=242) or gemcitabine plus cisplatin (n=122). A 
dose of 40 mg afatinib was administered orally, while gemcitabine 1000 
mg/m
2 
plus cisplatin 75 mg/m
2
 was given intravenously. Patients had a 
median age of 58 years. NSCLC with EGFR mutation(s), first-line treatment 
and ECOG performance status 0 or 1 were criteria for inclusion.  
LUX-Lung 6 
investigated efficacy 
and safety of afatinib in 
364 Asian patients 
 
 
 
median age of 58 years, 
ECOG performance 
status of 0 or 1  
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The primary endpoint in this trial was PFS, which was 11.0 months in the 
afatinib group compared to 5.6 months in the control group (HR 0.28, CI 
0.20–0.39, p<0.0001). Gains in PFS for afatinib were consistent across all 
subgroup analyses with a less pronounced benefit for patients with 
uncommon EGFR mutations and smokers with < 15 pack years who had 
stopped smoking for more than 1 year, but again, these subgroups comprised 
only few patients. Objective response rates were 66.9% in the afatinib group 
and 23.0% in the control group. The disease control rate was 92.6% in 
patients receiving afatinib compared with 76.2% of patients receiving 
gemcitabine/cisplatin. Data on OS are immature but amount to 22.1 months 
in patients receiving afatinib and 22.2 months in the control group (OR 0.95, 
CI NR, p=0.7593). 
Health-related quality of life was assessed using the European Organisation 
for Research and Treatment of Cancer’s quality of life questionnaire C30 
(EORTC QLQ-C30), a specific version for lung cancer patients (QLQ-LC13) 
and the EuroQol five-dimension questionnaire (EQ-5D). A higher 
proportion of afatinib-treated patients had symptom improvements in 
cough, dyspnoea and pain, and afatinib also significantly delayed time to 
deterioration for cough (HR 0.45, p=0.0001), dyspnoea (HR 0.54, p<0.0001) 
and pain (HR 0.70, p=0.03) compared with gemcitabine/cisplatin. Further, 
a significantly higher number of patients in the afatinib group had 
improvements in global health status/quality of life (63% vs. 33%, 
p<0.0001) compared with the control group. Also, improvements in 
functional scales were observed for the afatinib group (concerning physical, 
role, emotional, cognitive and social functioning). 
The most frequently reported AEs were diarrhoea (88.3%), rash/acne 
(80.8%) and stomatitis/mucositis (51.9%) with afatinib and vomiting 
(80.5%), nausea (75.2%) and neutropenia (54.0%) with 
gemcitabine/cisplatin. Drug-related AEs leading to dose reduction were 
observed in 32.2% in the afatinib group and in 26.5% in the control group, 
but discontinuation due to drug-related AEs was less frequent in the 
intervention group (5.9%) than in the gemcitabine/cisplatin group (39.8%). 
Drug-related serious AEs were 5.4% in the intervention group and 7.0% in 
the control group, while drug-related AEs leading to death occurred in 0.4% 
for afatinib and in 0.9% for gemcitabine/cisplatin. 
 
 
6.2 Efficacy and safety – further studies 
A phase II trial (LUX-Lung 2) [18] investigated the anti-tumour efficacy of 
afatinib in 129 patients. Patients whose disease progressed or relapsed after 
one chemotherapy regimen or chemotherapy-naïve patients with ECOG per-
formance status of 0–2 were included in the study. 99 Patients were treated 
with 50 mg afatinib once a day and 30 patients with 40 mg afatinib once a 
day until disease progression, intolerable adverse events or withdrawal. The 
proportion of patients with a confirmed objective response (complete re-
sponse or partial response) was the primary endpoint. 79 patients (69%) ex-
perienced an objective response (2 complete responses, 77 partial responses). 
Of 106 patients harbouring common EGFR mutations (exon 19 deletion or 
L858R), 70 patients (66%) had an objective response, while 9 (39%) of 23 pa-
tients with less common mutations experienced an objective response.  
PFS was extended by 5.4 
months in the afatinib 
group 
 
 
 
secondary endpoints 
and subgroup analyses 
favoured patients 
treated with afatinib 
assessment of quality of 
life  
 
afatinib delayed time to 
deterioration for cough, 
dyspnoea and pain 
 
patients treated with 
afatinib had higher 
improvement in global 
health status/quality of 
life 
AEs with afatinib: 
diarrhoea, skin-related  
AEs with chemotherapy: 
vomiting, nausea, 
neutropenia 
 
therapy discontinuation 
in 5.9% of patients with 
afatinib, 39.8% with 
chemotherapy 
LUX-Lung 2 investigated 
efficacy of afatinib in 
129 patients 
 
treatment with 50 mg 
or 40 mg afatinib 
 
objective response rate 
as primary endpoint 
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Grade 3 events of diarrhoea and rash/acne (the most common AEs) were 
more common in patients receiving 50 mg of afatinib than in the other 
group receiving 40 mg afatinib. 22 (22%) of 99 patients had diarrhoea and 28 
(28%) of 99 patients had rash/acne in the group receiving 50 mg afatinib, 
while 2 (7%) of 30 patients had diarrhoea and rash/acne in the group receiv-
ing 40 mg afatinib. Treatment-related serious AEs were less common in pa-
tients with 40 mg afatinib (2 of 30 patients vs. 14 of 99 patients) than in pa-
tients receiving a 50 mg dose. 
 
 
7 Estimated costs 
No cost estimates are yet available for Austria. 
 
 
8 Ongoing research 
At http://clinicaltrials.gov/ and https://www.clinicaltrialsregister.eu/ctr-
search/ 4 phase III studies investigating afatinib in patients with NSCLC 
were found. 
 NCT01121393: A randomised, open-label, phase III study to 
investigate the efficacy and safety of afatinib compared to standard 
first-line chemotherapy in patients with stage IIIB or IV 
adenocarcinoma of the lung harbouring an EGFR activating 
mutation. The estimated study completion date is May 2015. 
 NCT01853826: An open-label trial to evaluate the safety and 
tolerability of afatinib in patients with locally advanced or 
metastatic non-small cell lung cancer (NSCLC) harbouring EGFR 
mutation(s) and have never been treated with an EGFR TKI. The 
estimated study completion date is July 2015. 
 NCT01523587: A randomised, open-label phase III trial in patients 
with advanced squamous cell carcinoma of the lung requiring 
second-line treatment after receiving first-line platinum-based 
chemotherapy. The primary objective of this trial is to compare the 
efficacy of afatinib to erlotinib as second-line treatment in this 
group of patients. The estimated study completion date is November 
2015. 
 NCT01085136: A randomised, open-label, active-controlled, 
multicentre phase III study to determine the efficacy of afatinib 
given as an add-on to chemotherapy in patients with NSCLC stage 
IIIb or IV progressing after afatinib monotherapy compared to 
chemotherapy alone in this patient population. The estimated study 
completion is December 2015. 
 
diarrhoea and rash/acne 
were most common AEs 
 
treatment-related 
serious AEs occurred 
less common in patients 
with lower dose 
no cost estimates 
available  
4 ongoing phase III 
studies of afatinib in 
patients with NSCLC 
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Several other phase I and phase II studies are currently conducted in 
different treatment lines (first-line, second-line) in patients with NSCLC 
either with afatinib alone or in combination with other agents. Further, a 
large number of trials were identified investigating the effects of afatinib for 
example on head and neck cancer, esophagogastric cancer, prostate cancer 
and malignant glioma. 
 
 
9 Commentary 
In September 2013, the EMA granted marketing authorisation for afatinib 
(Giotrif
®
) for the treatment of EGFR TKI-naïve adult patients with locally 
advanced or metastatic NSCLC with activating EGFR mutations [2]. 
Afatinib (Gilotrif
®
) was approved by the FDA in July 2013 for the first-line 
treatment of patients with NSCLC whose tumours have EGFR mutations 
[6]. 
Two phase III studies (the LUX-Lung 3 and LUX-Lung 6 trial [3, 17, 19, 
22]) examined the efficacy and safety of afatinib as first-line therapy of 
EGFR TKI-naïve patients with advanced or metastatic NSCLC with 
activating EGFR mutations. The results of the LUX-Lung 6 study are only 
available in abstract or poster form so far. The trials compared treatment of 
patients either with afatinib or a double-agent chemotherapy. For patients 
treated with afatinib, median PFS was extended by 4.2 months (11.1 vs 6.9 
months, HR 0.58, p=0.001) [3] and 5.4 months respectively (11.0 vs 5.6 
months, HR 0.28, p<0.0001) [17]. Secondary endpoints including objective 
response rate and duration of response favoured patients treated with 
afatinib. Quality of life was also assessed, showing a significantly delayed 
time to deterioration for cough and dyspnoea in the afatinib group [22] but 
conflicting results for pain [19]. Improvements in global health-related 
quality of life and in functional scales were observed for patients receiving 
afatinib compared with chemotherapy [22].  
With afatinib the third EGFR TKI (besides erlotinib and gefitinib) is 
licensed for the first-line therapy of advanced NSCLC with EGFR 
mutations in Europe. The treatment paradigm has changed with the 
availability of these targeted therapies. Platinum-based double 
chemotherapy which has long been the standard treatment for the initial 
treatment of NSCLC is increasingly being replaced by EGFR TKIs. Even 
though the comparators used in the phase III studies therefore reflected 
common practice until recently, the head-to-head comparison of afatinib 
with erlotinib or gefitinib is of great interest (a phase IIb trial of afatinib 
versus gefitinib for the first-line treatment of EGFR mutation NSCLC is 
currently conducted and the estimated study completion date is December 
2014 (NCT01466660). These comparative trials may also assist in eliciting 
whether emergence of secondary resistance is less common with the 
irreversible EGFR TKI afatinib than with the reversible inhibitors erlotinib 
and gefitinib [19]. Since aquired resistance eventually develops in all 
patients treated with a TKI [23] and afatinib has shown some activity in 
patients with resistance to erlotinib and gefitinib, futher clinical data for 
this setting will also help in better describing the role of afatinib for the 
treatment of NSCLC [24].  
afatinib also 
investigated in different 
treatment lines and 
indications 
approved by the EMA 
and the FDA 
two phase III studies 
(LUX-Lung 3 and LUX-
Lung 6  investigated 
afatinib compared with 
chemotherapy 
 
median PFS was 
extended by 4.2 months 
and 5.4 months in 
patients with afatinib 
 
improvements in quality 
of life were observed 
with afatinib 
afatinib is the third TKI 
for advanced NSCLC 
with EGFR mutations 
 
studies comparing 
afatinib, erlotinib and 
gefitinib directly are 
important 
 
 
 
 
further studies are 
needed concerning 
acquired resistance in 
irreversible agent 
afatinib compared with 
reversible inhibitors 
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Phase III studies on EGFR TKIs have primarily been conducted in Asian 
patients [25, 26] and also the LUX-Lung 3 study comprised 72% of patients 
with Asian ethnicity [3], raising the question of transferability of the 
positive effects of afatinib to Caucasians. In addition, further clarification is 
needed in terms of efficacy of afatinib for certain subgroups of patients, 
primarily concerning common and uncommon EGFR mutations. Both 
phase III trials presented results for these two groups and yielded less 
favourable outcomes in PFS for those with uncommon mutations. However, 
PFS was still significantly higher in this subgroup than with chemotherapy. 
Further, data on quality of life indicate that better symptom improvement 
and control can be achieved the larger PFS gains are [27]. Since these 
subgroups comprised only few patients, investigations specifically targeting 
individuals with uncommon mutations are of interest to further describe 
patients with the potential to benefit the most from afatinib therapy. 
In terms of safety, AEs were common in the afatinib and in the 
chemotherapy groups, but distinct differences in the toxicity profiles exist. 
A dose reduction was required for more than 50% of the study participants 
with 19% of all patients requiring more than one dose reduction [3]. Drug-
related serious AEs were 5.4% in the afatinib group and 7.0% in the control 
group [22]. Therapy was discontinued because of treatment-related AEs in 
8% of the patients receiving afatinib and 12% of the patients receiving 
cisplatin plus pemetrexed [3]. Related AEs leading to death occurred in 
0.4% for afatinib and in 0.9% for gemcitabine/cisplatin [22]. Despite this 
manageable side-effect profile, data on long-term use is missing. This is of 
particular importance because EGFR TKI first-line therapy and a 
combination with chemotherapy even after disease progression are options 
for the treatment of EGFR mutation-positive NSCLCs. Thus, the duration 
of TKI therapy may be a substantial factor. 
 
Finally, even though the costs for afatinib are not yet known, a potentially 
long-term treatment duration with this TKI, probably in combination with 
other drugs and repeated testing for EGFR mutations, will inevitably impact 
on treatment costs even though rather few patients will qualify for this 
therapy in Europe because the frequency of activating EGFR mutations in 
Caucasian patients ranges from 9% to 15% in contrast to up to 65% in 
Asians [13]. 
 
transferability of 
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patients unclear 
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analyses for 
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distinct toxicity profiles 
in the afatinib and in the 
chemotherapy group, 
but data on long-term 
use is missing 
 
duration of TKI therapy 
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influenced by testing for 
EGFR mutations  
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